PD1/PD-L1在卵巢癌及癌旁组织的表达及与临床病理、预后的关系

The expression of PD1/PD⁃L1 in ovarian cancer and adjacent tissues and its relationship with clinical pathology and prognosis

目的探究程序性死亡受体1(PD1)/细胞程序性死亡配体1(PD-L1)在卵巢癌及癌旁组织的表达及与临床病理、预后的关系。方法选取沧州市中心医院2021年12月至2022年12月收治的120例卵巢癌患者,对患者癌组织及癌旁组织PD1、PD-L1表达情况进行检测,采用多因素logistic回归分析与Kaplan-Meier法探究PD1、PD-L1与患者临床病理、预后的关系。结果120例患者中,卵巢癌组织中PD1阳性32例(26.67%)(PD1阳性组),PD-L1阳性39例(32.50%)(PD-L1阳性组),其中有30例(25.00%)患者同时表达PD1、PD-L1(表达组),79例(65.83%)患者均未出现PD1、PD-L1表达(未表达组)。癌旁组织中均未见两者表达。PD1、PD-L1阳性组与PD1、PD-L1阴性组病理类型、国际妇产科联盟(FIGO)分期比较差异有统计学意义(P<0.05)。多因素logistics回归分析显示,病理类型、FIGO分期为PD1、PD-L1表达的影响因素(P<0.05)。120例患者中共39例复发,PD1阳性组、PD-L1阳性组、表达组、未表达组复发率为50.00%、56.41%、60.00%、12.68%,四组无进展生存时间(PFS)为(18.04±1.68)个月、(17.96±1.42)个月、(16.73±1.05)个月、(20.06±1.75)个月。结论PD1、PD-L1在卵巢癌中的表达提示患者预后不良,临床应采取针对性措施对PD1阳性、PD-L1阳性的患者进行干预,以改善预后。

Objective To investigate the expression of programmed death 1(PD1)/programmed death ligand⁃1(PD⁃L1)in ovarian cancer and adjacent tissues,and its relationship with clinical pathology and prognosis.Methods 120 ovarian cancer patients admitted to Cangzhou Central Hospital from December 2021 to December 2022 were selected for this study.The expression of PD1 and PD⁃L1 in cancer tissues and adja⁃cent tissues was examined.Multivariate logistic regression analysis and Kaplan⁃Meier analysis were performed to explore the relationship among PD1,PD⁃L1,clinical pathology and prognosis.Results Among the 120 pa⁃tients,there were 32(26.67%)cases that were PD1 positive(PD1 positive group)and 39(32.50%)cases that were PD⁃L1 positive cases(PD⁃L1 positive group).Simultaneous expression of PD1 and PD⁃L1 was ob⁃served in 30(25.00%)patients(expression group).No expression of PD1 or PD⁃L1 was observed in 79(65.83%)patients(non⁃expression group).There was no PD1 or PD⁃L1 expression in adjacent tissues.Statisti⁃cally significant differences were found in pathological types and FIGO staging between the PD1/PD⁃L1 posi⁃tive group and the PD1/PD⁃L1 negative group(P<0.05).Multivariate logistic regression analysis found that pathological type and FIGO stage were influencing factors of PD1 and PD⁃L1 expression(P<0.05).Out of 120 patients,39 experienced recurrences.The recurrence rates in the PD1 positive group,PD⁃L1 positive group,expression group and non⁃expression group were 50.00%,56.41%,60.00%and 12.68%,respectively.PFS of the four groups were(18.04±1.68)months,(17.96±1.42)months,(16.73±1.05)months and(20.06±1.75)months.Conclusion The expression of PD1 and PD⁃L1 in ovarian cancer tissues suggests a poor prog⁃nosis.Clinically,targeted measures should be taken for PD1 positive and PD⁃L1 positive patients to improve their prognosis.